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Abstract Two overlapping quantitative trait loci (QTLs)
for clot stability, Hmtb8 and Hmtb9, were identiﬁed on
mouse chromosome 17 in an F2 intercross derived from
C57BL/6J (B6) and B6-Chr17
A/J (B6-Chr17) mouse
strains. The intervals were in synteny with a QTL for
thrombotic susceptibility on chromosome 18 in a human
study, and there were 23 homologs between mouse and
human. The objective of this study was to determine
whether any of these genes in the syntenic region are likely
candidates as modiﬁers for clot stability. Seven genes,
Twsg1, Zfp161, Dlgap1, Ralbp1, Myom1, Rab31, and
Emilin2, of the 23 genes with single nucleotide polymor-
phisms (SNPs) in the mRNA-UTR had differential
expression in B6 and A/J mice. Dlgap1, Ralbp1, Myom1,
and Emilin2 also had nonsynonymous SNPs. In addition,
two other genes had nonsynonymous SNPs, Lama1 and
Ndc80. Of these nine candidate genes, Emilin2 was selec-
ted for further analysis since other EMILIN (Elastin
Microﬁbril Interface Located Protein) proteins have known
functions in vascular structure and coagulation. Differences
were found between B6 and A/J mice in vessel wall
architecture and EMILIN2 protein in plasma, carotid vessel
wall, and thrombi formed after ferric chloride injury. In
B6-Chr17
A/J mice both clot stability and Emilin2 mRNA
expression were higher compared to those in B6 and A/J
mice, suggesting the exposure of epistatic interactions.
Although other homologous genes in the QTL region
cannot be ruled out as causative genes, further investigation
of Emilin2 as a candidate gene for thrombosis suscepti-
bility is warranted.
Introduction
Thrombosis occurs as a consequence of vascular injury due
to an imbalance between the pathways that regulate
thrombus formation and/or dissolution and is the major
fatal event of cardiovascular diseases (Voetsch and Los-
calzo 2004). Great strides have been made in the diagnosis
and treatment of thrombosis in the last decade. However,
strategies to prevent thrombosis have lagged far behind
partly because of the contribution of multiple and as yet
undeﬁned genetic factors that lead to thrombotic risk.
Moreover, it remains unclear how genetic background
inﬂuences the function of molecules and pathways known
to regulate thrombus formation and lysis, thereby contrib-
uting to the risk of thrombotic disease (Ginsburg 2005).
To investigate genetic differences in thrombosis, we
identiﬁed two inbred mouse strains, B6 and A/J, that have
marked differences in a tail bleeding/rebleeding assay and
response to FeCl3-induced carotid injury (Hoover-Plow
et al. 2006). In the tail bleeding/rebleeding assay, an
established hemostasis and thrombosis reporter assay, there
was no difference in the ﬁrst bleeding time between the B6
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bleeding to occur was increased in A/J mice compared to
B6 mice by nearly threefold, indicating enhanced clot
stability (Hoover-Plow et al. 2006) in the A/J mice. A
marked difference of twofold in arterial thrombus occlu-
sion time was found between the B6 and the A/J mice in
the FeCl3 carotid artery injury model.
Surveying a panel of 21 chromosome substitution strains
(CSS) in which individual A/J chromosomes were replaced
in a B6 background, three chromosomes were identiﬁed
with modiﬁer genes for clot stability (Hoover-Plow et al.
2006): Hmtb1 (chromosome 5), Hmtb2, (chromosome 11),
and Hmtb3 (chromosome 17). Quantitative trait locus
(QTL) analysis was performed in F2 mice (B6 9 B6-Chr5,
B6-Chr11, and B6-Chr17 strains) and QTL mapping led to
identiﬁcation of a signiﬁcant locus on chromosome 5
(Hmtb4), a suggestive locus on chromosome 11 (Hmtb5),
and two suggestive overlapping QTLs on mouse chromo-
some 17 (Hmtb8, 9). The mouse QTL intervals on chro-
mosome 17 are in synteny with a previously identiﬁed QTL
for thrombosis risk on human chromosome 18 (Soria et al.
2003). The syntenic region contains 23 homologous genes
and the purpose of this study was to determine whether any
of these genes in the syntenic region are likely candidates
as modiﬁers for clot stability.
Differential expression in B6 and A/J mice in seven of
the homologous genes with SNPs in the regulatory
regions was conﬁrmed. One of the genes expressed in the
cardiovascular system, Emilin2, was differentially
expressed in lung of B6, A/J, and B6-Chr17 mice and in
liver and bone marrow of B6 and A/J mice. Sequence
analysis of Emilin2 identiﬁed novel SNPs in the coding
and promoter regions between B6 and A/J that could alter
expression and/or protein–protein interactions. In B6-
Chr17 mice clot stability and Emilin2 expression was
higher than in A/J mice, suggesting that there is a
modiﬁer gene from another chromosome. EMILIN2
protein was found in platelets, aorta, macrophages,
plasma, vessel wall, and thrombi. EMILIN2 may regulate
thrombosis by maintaining vessel architecture and/or clot
lysis susceptibility. Our data support further investigation
of Emilin2 as a promising candidate modiﬁer gene for
thrombosis risk.
Methods
Mice
The inbred strains B6 (#000664) and A/J (#000646) were
obtained from the Jackson Laboratory (Bar Harbor, ME) at
6 weeks of age. B6-Chr17 mice with A/J chromosome 17
in a B6 background, previously described (Nadeau et al.
2000; Singer et al. 2004), were provided by Dr. Nadeau or
by Jackson Laboratory (#004395) and housed and bred at
the Biological Resource Unit at the Cleveland Clinic
Lerner Research Institute. Experiments were carried out on
mice between 7 and 9 weeks of age. All animal experi-
ments were performed in accordance with a protocol
approved by the Institutional Animal Care and Use Com-
mittee at the Cleveland Clinic.
RT-PCR and real-time PCR
Total RNA was puriﬁed from the tissues and the cells of
A/J and B6 mice using the RNeasy Mini Kit (Qiagen,
Valencia, CA), treated with TURBO DNase (Ambion,
Austin, TX), and reverse transcribed into cDNA using
SuperScript
TM III First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, CA) according to the
manufacturers’ instructions. RT-PCR was performed using
50 ng of cDNA from A/J and B6 mice as templates. The
PCR product was analyzed on 1 or 1.2% agarose gel and
recovered using the QIAquick Gel Extraction Kit (Qiagen).
Sequencing (ABI 3730xl, Applied Biosystems, Foster City,
CA) was performed at the Genomic Core of Cleveland
Clinic. Negative controls that cannot undergo reverse
transcription were included in the cDNA synthesis step.
Real-time PCR was performed using an iCycler iQ (Bio-
Rad Laboratories, Hercules, CA). Each ampliﬁcation
reaction contained 20 ng of cDNA, 300 nM of each primer,
25 llo f29 power SYBR
 Green Master Mix (Applied
Biosystems, Warrington, UK), and 0.5 ll of UNG (Applied
Biosystems) added to prevent carryovers. Samples were
normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH, Operon, Huntsville, AL). The comparative cycle
threshold method was used to analyze the data. RNA was
isolated from ﬁve to six mice for each group and analyzed
in triplicate. All the primers are listed in Supplementary
Table 1.
PCR for cloning promoters and noncoding regions
Genomic DNA was isolated from hearts of A/J and B6
mice using a DNA Mini Kit (Qiagen). In order to minimize
errors, Expand High Fidelity PCR system (Roche, India-
napolis, IN) was used for PCR. The 25-ll reaction system
contained 100 ng of DNA template and 200 nM of each
primer (listed in Supplementary Table 1). The estimated
error with this method is approximately 3/10
5 bp. As
above, the PCR product was analyzed on agarose gel,
recovered, and sequenced by the Genomic Core at the
Cleveland Clinic. The cloning and sequencing was repe-
ated twice and the same sequencing results were found.
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123Generation of EMILIN2 anti-peptide antibody
A polyclonal antibody (E185) for mouse EMILIN2 was
generatedinrabbits.SinceEMILIN2hasahighhomologyto
EMILIN1,apeptidewassynthesizedfromresidues829–843
located in the proline-rich domain speciﬁc to EMILIN2. To
increase the speciﬁcity of the antibody, the rabbit antiserum
was subjected to afﬁnity puriﬁcation using the peptide. To
test the speciﬁcity of the antibody, HEK293 cells were
transfected with the construct E2-N1 that contains EMI-
LIN2-EGFP fusion gene and construct PR-N1 that harbors
the PR domain–EGFP fusion gene. The vector N1 that
contains only the EGFP gene was used as negative control.
Constructs containing EMILIN2 protein domains, namely,
Collagen-like C1q domains that do not interact with the
antibody,andEGFPfusiongenes,werealsousedasnegative
controls. Using the puriﬁed antibody, Western blot detected
a single band at approximately 150 kDa, which is the pre-
dicted molecular weight for the EMILIN2-EGFP fusion
proteinfromtheE2-N1constructandapproximately50-kDa
band for the PR-EGFP fusion protein. In contrast, no band
was detected from the cells transfected with vector alone or
the Col-EGFP andC1q-EGFP constructs.Using anantibody
against EGFP, the same 150-kDa single band was detected
from cells transfected with E2-N1 and a 50-kDa band was
detected for PR-EGFP. On the other hand, only one band
around 30 kDa (EGFP) was detected from cells transfected
with N1 vector. The EGFP antibody also detected the
domain-EGFP fusion proteins with the predicted molecular
weight for each construct; this indicates that E185 binds
speciﬁcally to the PR region of EMILIN2.
Western blotting
The mice were perfused with PBS and aortas were har-
vested, homogenized, and lysed in RIPA buffer (R0278,
Sigma, St. Louis, MO) with protease inhibitors (P8340,
Sigma). Platelets were gel ﬁltration puriﬁed and lysed with
RIPA buffer with protease inhibitors. Plasma was collected
by centrifuging citrated blood at 1000 g for 10 min and
mixed with 2 9 Laemmli sample buffer (Bio-Rad). Perito-
neal lavage was collected 72 h after treatment, with 0.5 ml
of 4% thioglycollate and peritoneal macrophages were
harvested, washed with PBS, and suspended in RIPA buffer.
About 95% of the cells were macrophages, identiﬁed by
Wright’s staining, and the viability was greater than 95%, as
assessed by trypan blue staining. Protein concentration was
measured with the Protein Assay (Bio-Rad). For Western
blots, 10 lg of protein was loaded in each lane for SDS-
PAGE gels, which were transferred to PVDF membranes.
The membranes were incubated with rabbit anti-EMILIN2
(E185), goat anti-EMILIN2 (Q-16, sc-51356, Santa Cruz
Biotechnology, Santa Cruz, CA) and EMILIN1 (sc-27569,
Y-13, Santa Cruz) antibodies, and HRP-conjugated anti-
rabbit or anti-goat secondary antibodies. Protein bands were
detected using the ECL detection system (GE Healthcare,
Buckinghamshire, UK). A protein loading control, b-actin,
was detected with antibody (A5441, Sigma).
FeCl3 carotid injury and immunohistochemical staining
To induce thrombus formation in the carotid artery, a ferric
chloride (FeCl3) model of vessel injury was employed as
previously described (Hoover-Plow et al. 2006). The ﬂow
probe (model 0.5PSB, Transonic Systems, Ithaca, NY) was
in place from baseline measurements to several minutes
after the stable occlusion had been reached or stopped at
30 min if it had not occluded. Blood ﬂow was recorded
every 10 s (model TS420, Transonic Systems). After car-
diac perfusion, the carotid arteries were harvested after
occlusion, immediately embedded into OCT (Tissue-Tek,
Torrance, CA), and frozen. The frozen carotid arteries were
sectioned at 10 lm using a cryostat (Leica CM1850, Leica
Microsystems, Nassloch, Germany), ﬁxed with acetone at
4C for 10 min, then blocked with normal serum. EMI-
LIN2 was detected with E185 or Q-16 antibodies and
P-selectin with rabbit anti-CD62P antibody (BD Biosci-
ences, San Diego, CA). The sections were then incubated
with 1:1000 diluted biotinylated appropriate secondary
antibodies (PK-6101, PK-6105 Vectastain ABC Kit, Vector
Laboratories, Burlingame, CA), and proteins were visual-
ized with alkaline phosphatase substrate. For quantiﬁcation
Table 1 Patency in B6, A/J, and B6-Chr17 mice in FeC13-induced
vascular injury
Open percentage Mean blood ﬂow
(ml/min)
B6 Baseline 0.48 ± 0.08
A/J Baseline 0.47 ± 0.07
2h
B6 0% (0/5) 0.05 ± 0.01
A/J 0% (0/5) 0.04 ± 0.01
4h
B6 44% (4/9) 0.22 ± 0.06
A/J 22% (2/9) 0.16 ± 0.02
B6-Chr17 0% (0/4) 0.06 ± 0.01
24 h
B6 90% (9/10) 0.45 ± 0.08*
A/J 64% (7/11) 0.31 ± 0.08**
B6-Chr17 0% (0/6) 0.05 ± 0.01
When blood ﬂow is less than 0.1 ml/min, it is assumed that the carotid
is closed. Mouse numbers with open carotids/total mouse numbers are
in parentheses. Symbols indicate a difference between B6-Chr 17 and
B6 (* P\0.01) and A/J (** P\0.05)
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123analysis, six sections of each carotid and six mice from each
group were measured and analyzed using Image-Pro Plus
(Media Cybernetics, Silver Spring, MD).
Statistical analysis
Values are presented as mean ± SEM. Statistical differ-
ences were assayed by a t test or ANOVA with Newman-
Keuls post-test.
Results
Clot stability is enhanced in A/J and B6-Chr17 mice
compared to B6 mice
Previously we reported prolonged clot stability times in the
tail bleeding/rebleeding assay and rapid occlusion time
after FeCl3-induced carotid injury in A/J mice compared to
B6 mice (Hoover-Plow et al. 2006). A tail bleeding/reb-
leeding assay suitable for large-scale screening was used to
screen a panel of CSS mice. We identiﬁed that the B6-
Chr17 mice (the strain containing A/J Chr 17 in the B6
background) had similar clot stability times as those of the
A/J strain, suggesting that Chr 17 contains a gene or genes
responsible for this phenotypic variation. We tested this
phenotypic variation using another model, the FeCl3-
induced carotid injury in B6-Chr17, A/J, or B6 mice, to
validate the results from the bleeding/rebleeding assays. In
the B6-Chr17 mice, the occlusion time, reﬂecting clot
formation, was similar to the B6 times. Measuring the
blood ﬂow at 0, 2, 4, and 24 h following administration of
FeCl3 tested the patency of the carotids after injury. In both
A/J and B6 strains, carotids remained occluded at 2 h. At
4 h, 44% of the vessels were open in the B6 compared to
only 22% in the A/J and 0% in the B6-Chr17 (Table 1). At
24 h, 90% of the B6 mice had open carotids while only
64% of A/J and 0% of B6-Chr17 mice had open carotids.
Blood ﬂow at 24 h was signiﬁcantly less in the B6-Chr17
mice than both B6 (P\0.01) or A/J (P\0.05) mice.
These results suggest that Chr 17 contains candidate genes
responsible for the thrombotic susceptibility variation in
A/J and B6 mice and that the candidate gene(s) regulate the
clot stability/clot lysis rather than clot formation. In addi-
tion, the signiﬁcant difference in patency observed with
B6-Chr17 or A/J mice suggests that genes from the B6
background on other chromosomes interact with the caus-
ative genes on Chr 17.
Expression of homologous genes
The syntenic region for the mouse and human QTLs
spanned 5.9 Mb and contained 23 homologs retrieved from
the Ensembl Genome Browser (Fig. 1). To test the
expression of the candidate genes, real-time PCR was
performed and mRNA levels of the 23 genes were analyzed
from the liver of A/J and B6 mice (Table 2). Three of the
genes were not expressed in the liver: Txndc2, Lrrc30, and
Myom1. Expression of six of the genes, Rab12, Zfp161,
Emilin2, Twsg1, Ankrd12, and Dlgap1 (indicated in bold in
Table 2), was signiﬁcantly higher (1.6-2.7-fold) in A/J than
in B6, suggesting the possibility that these six genes could
be candidate genes. The increased expression of EMILIN2
is not indicative of a systematic error. GAPDH was used as
the endogenous control for every sample in every analysis,
and GAPDH expression levels were similar in the two
strains. One possible explanation for the increase in
expression in A/J is that A/J has higher gene copy numbers
in this region which may alter expression (Cutler et al.
2007; Graubert et al. 2007; Henrichsen et al. 2009; She
et al. 2008). In addition, the microarray data from Hen-
richsen et al. (Microarray data, C. N. Henrichsen et al.,
Record GSE10744, released in 2009 from Gene Express
Omnibus) found differential expression in B6 and A/J in
lung for Ralbp1, Twsg1, Ptprm, and Ebp4.1l3 and in heart
for Rab31, Ptprm, Myom1, and Emilin2. Thus, of the 23
genes in the homologous region, 11 had differential
expression in B6 and A/J mice.
SNPs in the homologous genes
SNPs in the homologous genes were retrieved from the
MGI dbSNP Build 128 and the recently available Sanger
18p11.32
18p11.31
18p11.22
NDC80
SMCHD1
EMILIN2
LPIN2
MYOM1
TGIF1
DLGAP1
EPB4.1L3
ARHGAP28
LAMA1
LRRC30
PTPRM
RAB12
NDUFV2
ANKRD12
TWSG1
RALBP1
PPP4R1
RAB31
TXNDC2
VAPA
ZFP161
MYL12B
Human
9.9Mb
2.6Mb Vapa
Txndc2
Rab31
Ppp4r1
Ralbp1
Twsg1
Ankrd12
Ndufv2
Rab12
Ptprm
Lrrc30
Lama1
Arhgap28
Epb4.1l3
Zfp161
Tgif
Myl12b
Myom1
Lpin2
Emilin2
Smchd1
Ndc80
Mouse
Dlgap1
65.9Mb
71.9Mb
Fig. 1 Genes in the mouse QTL region and the human syntenic
region were determined using Ensembl Genome Browser. Symbols of
the genes are indicated. Names of the genes can be found in Table 1
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123database of A/J chromosome 17 (Table 3). In addition to
the coding region, mRNA-UTR (mRNA-untranslated
region), introns, and SNPs 2 kb upstream and downstream
of the genes are recorded in the MGI database. The SNPs
identiﬁed from the MGI database were also identiﬁed in the
Sanger database. The read depth (number of paired reads
mapping Chr17_36/length of Chr17) (Sudbery et al. 2009)
of the SNPs in the Sanger database was high, 7-22. In many
genes, due to the thorough sequencing coverage of the A/J
Chr 17, additional SNPs were identiﬁed, especially in the
introns of the genes in the Sanger database. Two genes,
Txndc2 and Rab12, did not contain any SNPs in A/J or B6
(Table 3). Five genes, Vapa, Ankrd12, Ndufv2, Arhgap28,
and Ptprm, had no nonsynonymous SNPs in the coding
regions or SNPs in the mRNA-UTR or upstream or
downstream noncoding regions (Table 3). Therefore, these
seven genes are not likely to be causative genes.
Six genes, Ralbp1, Lama1, Dlgap1, Myom1, Emilin2,
and Ndc80, had nonsynonymous SNPs in the coding
region. Twelve genes, Rab31, Ppp4r1, Ralbp1, Twsg1,
Zfp161, Dlgap1,Tgif, Myom1, Lpin2, Emilin2, Smchd1, and
Ndc80, had SNPs in the mRNA-UTR. Eleven genes had
SNPs in the 2-kb noncoding regions: Ppp4r1, Ralbp1,
Lrrc30, Epb4.1l3, Zfp161, Tgif, Myl12b, Myom1, Lpin2,
Emilin2, and Smchd1. Although not determined in this
study, regions outside the 2-kb region could also alter the
expression of genes. Thus, 16 of the 23 homologous genes
had SNPs in the coding region or mRNA-UTR and could
be candidate genes. Four of these genes, Twsg1, Zfp161,
Dlgap1, and Emilin2, with SNPs in the mRNA-UTR, also
had differential expression in liver of B6 and A/J mice,
suggesting that these four genes have great potential to be
candidate genes. In addition, Ralbp1, Myom1, and Rab31
were reported to be differentially expressed in lung or heart
(Microarray data, C. N. Henrichsen et al., Record
GSE10744, released in 2009 from Gene Express Omnibus).
Thus, for 7 of the 16 genes with SNPs in the regulatory
regions, differential expression was conﬁrmed. Two genes,
Lama1 and Ndc80, had nonsynonymous SNPs. These nine
genes (7 with SNPs in regulatory regions and differential
expression plus 2 genes with nonsynonymous SNPs) were
considered to be candidate genes and their known functions
and distribution were evaluated.
Of the known functions and distribution of the genes and
gene products identiﬁed above with SNPs in the mRNA-
UTR and/or nonsynonymous SNPs, Emilin2 seemed the
most likely candidate gene. Because EMILIN2 and other
EMILIN proteins are associated with the cardiovascular
Table 2 Expression analysis of
the homologous genes in the
syntenic QTL interval by real-
time PCR
Fold changes of mRNA
expression of the genes in A/J
compared to B6 and the
P values are indicated. n = 6.
Genes with signiﬁcant
difference between A/J and B6
are shown in bold
ND not detected
Symbol Name Fold change P value
Vapa VAMP-associated protein A 1.28 0.19
Txndc 2 Thioredoxin domain containing 2 ND –
Rab31 Member RAS oncogene family 1.13 0.45
Ppp4r1 Protein phosphatase, regulatory subunit 1 1.24 0.43
Ralbp1 ralA binding protein 1 1.45 0.27
Twsg1 Twisted gastrulation homolog 1 (drosophila) 1.63 0.001
Ankrd12 Ankyrin repeat domain 12 2.26 0.0025
Ndufv2 NADH dehydrogenase ﬂavoprotein 2 1.39 0.19
Rab12 RAB12, member RAS oncogene family 2.15 0.01
Ptprm Protein tyrosine phosphatase receptor M 1.25 0.31
Lrrc30 Leucine-rich repeat containing 30 ND –
Lama1 Laminin, alpha 1 0.71 0.89
Arhgap28 Rho GTPase activating protein 28 1.69 0.29
Epb4.1l3 Erythrocyte protein band 4.1-like 3 1.31 0.33
Zfp161 Zinc ﬁnger protein 161 2.74 0.01
Dlgap1 Large (drosophila) homolog-associated protein 1 1.96 0.035
Tgif TG interacting factor 1.04 0.83
Myl12b Myosin light chain 12 B regulatory 1.86 0.10
Myom1 Myomesin 1 ND –
Lpin2 Lipin2 1.79 0.12
Emilin2 Elastin microﬁbril interfacer 2 1.58 0.005
Smchd1 SMC hinge domain containing 1 1.28 0.25
Ndc80 Kinetochore complex component 1.41 0.26
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123system (Christian et al. 2001; Hayward et al. 1993, 2004;
Lembertas et al. 1997; Milanetto et al. 2008), we selected
Emilin2 for further analysis. In addition to differential
expression in B6 and A/J mice, Emilin2 had nonsynony-
mous SNPs in the coding region and SNPs in the potential
regulatory regions, based on the MGI and Sanger dat-
abases. Because Emilin2 could be a causative gene in this
QTL, examination of the expression and polymorphisms
was undertaken with B6, A/J, or B6-Chr17 mouse strains.
Expression of Emilin2 in lung, bone marrow cells,
heart, and aorta
The mRNA expression of Emilin2 was determined by
quantitative real-time PCR in lung, heart, aorta, and bone
marrow cells. There was a 4.3-fold increase in Emilin2
mRNA expression in the lungs of A/J mice compared to B6
mice (P = 0.005) (Table 4). Expression of Emilin2 in the
lungs of B6-Chr17 or A/J mice was 4.8-fold (P = 0.0004)
or 3.8-fold (P = 0.004) higher, respectively, compared to
B6 mice (Fig. 2). There was no signiﬁcant difference in
expression of Emilin2 in heart and aorta tissue between the
two strains (Table 4). In the GEO microarray data, Emilin2
in the lung was 1.4-fold higher in A/J than in B6, which is
consistent with increased Emilin2 expression in A/J in our
data. However, because of the standard deviation in A/J
mice (n = 3) in the microarray data, there was no signiﬁ-
cant difference between A/J and B6. In the heart, Emilin2
was 60% lower in A/J than in B6 mice in the microarray
data, and in our study Emilin2 expression was 44% lower
in A/J than in B6 mice. In our data, because of high
standard deviation, there was no signiﬁcant difference
between A/J and B6 expression. However, the tendency of
Table 3 Mouse genes on Chr 17 homologous to genes in human QTL on Chr 18
Symbol ID (MGI) Start Coding region Noncoding regions
Synonymous Nonsynonymous Upstream Downstream mRNA-UTR Intron
Vapa 1353561 65929396 1 (1)
Txndc2 Txndc2 65986854
Rab31^ 1914603 66001069 1 234 (54)
Ppp4r1^ 1917601 66169485 1 (1) (5) (4) 1 (1) 135 (38)
Ralbp1#^ 108466 66197781 3 (3) 1 (5) (4) 3 (1) 101 (39)
Twsg1^ 2137520 66272406 3 (3) 15 (11)
Ankrd12 1914357 66316841 7 (4)
Ndufv2 1920150 66428135 5 (3)
Rab12 894284 66843852
Ptprm 102694 67016883 1 (1) 2428 (647)
Lrrc30 2685172 67981021 (1)
Lama1# 99892 68046605 9 (1) 5 (1) 242 (21)
Arhgap28 2147003 68192053 1
Epb4.1l3 103008 69506150 (2) 14 (11)
Zfp161^ 1195345 69732390 (1) 2 1
Dlgap1#^ 1346065 70318413 1 (1) 1 5 2428 (216)
Tgif^ 1194497 71193551 (1) 2 (1) 2 (1)
Myl12b 107494 71323260 (3)
Myom1#^ 1341430 71368861 8 5 (1) (1) 3 417 (119)
Lpin2^ 1891341 71531900 2 (1) (2) 6 (6) 88 (48)
Emilin2#^ 2389136 71601516 11 (8) 12 (3) (3) 4 375 (82)
Smchd1^ 1921605 71693829 1 (1) (5) 2 284 (125)
Ndc80#^ 1914302 71845442 4 (3) 1 (1) 2 (1) 86 (55)
SNPs were retrieved from the Wellcome Trust Sanger Institute Mouse Genome Project and the MGI dbSNP Build 128 (in parenthesis). MGI IDs
are indicated. The start site of the gene on mouse chromosome 17 was retrieved from Ensembl annotation of the NCBI Build 37. Synonymous
SNPs are SNPs in the coding region with no amino acid change. Nonsynonymous SNPs are SNPs with an amino acid change. Upstream is the
region 2 kb from the 50 coordinate. Downstream is the region 2 kb downstream from the 30 coordinate. mRNA-UTR indicates SNPs in the
mRNA-untranslated region. Items in the Symbol column with no symbol means that there are no SNPs in the nonsynonymous coding regions or
SNPs in the mRNA-UTR; # = nonsynonymous SNPs in the coding region; ^ = SNPs in the mRNA UTR. Genes with differential expression in
B6 and A/J mice are indicated in bold
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123reduced expression of Emilin2 in the heart of A/J mice is
consistent in both analyses. The microarray data were from
only three mice, aged from 11 to 14 weeks, in each group;
our data were from six (lung) or ﬁve (heart) mice, aged
from 6 to 8 weeks, in each group.
Since Doliana et al. (2001) demonstrated a robust
expression of Emilin2 mRNA in peripheral leukocytes,
bone marrow cells were tested for Emilin2 mRNA
expression. Emilin2 expression was twofold higher
(P = 0.04) in bone marrow cells from A/J than from B6
mice (Table 4). In addition, the expression level of Emilin2
was over tenfold higher in bone marrow cells than in other
tissues from the same strain. Bone marrow has hemato-
poietic cells, including red cells and platelets important for
blood clotting. Differences in expression of Emilin2 in
tissue and bone marrow between B6, A/J, and B6-Chr17
along with prolonged clot stability in B6-Chr17 suggest
that Emilin2 may be a candidate gene for thrombosis
susceptibility.
Nucleotide polymorphisms in Emilin2
To verify the SNPs identiﬁed in the databases, the protein
sequence of Emilin2 was determined for B6 and A/J mice.
Emilin2 cDNAs were cloned from A/J or B6 mice by
RT-PCR and sequenced in duplicate. The sequences for
each strain (B6 GenBank ID GQ872460, A/J GenBank ID
GQ872457) were identical from two experiments. The B6
Emilin2 sequence GQ872460 is identical to C57BL/6
Emilin2 sequence NM_145158 from the NCBI GenBank.
The predicted amino acid sequences identiﬁed 11 amino
acid polymorphisms between the two strains (Table 5).
Three amino acids, 571, 662, and 834, exist in the SNP
database (MGI dbSNP Build 128), while the Sanger
Table 4 EMILIN2 expression by quantitative real-time PCR in tissue
Tissue B6 A/J P value Fold change
of A/J from B6
Fold change
from liver B6
Fold change
from liver A/J
Liver 0.50 ± 0.05 0.79 ± 0.06 0.005 1.58 1 1
Lung 1.50 ± 0.65 6.45 ± 1.42 0.01 4.30 3.00 8.16
Heart 1.93 ± 0.32 1.08 ± 0.17 ns 0.56 3.86 1.37
Aorta 2.60 ± 0.49 3.44 ± 0.96 ns 1.32 5.20 4.35
Bone marrow 32.5 ± 8.06 65.2 ± 10.58 0.03 2.01 65.00 82.53
B6, A/J: samples were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Operon, Huntsville, AL). The comparative cycle
threshold method was used to analyze the data. RNA was isolated from ﬁve or six mice for each group and analyzed in triplicate. All the primers
are listed in Supplementary Table 1
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Fig. 2 Expression of Emilin2 in lung from A/J, B6, and B6-Chr17,
n = 5. GAPDH from the same cDNA samples used as endogenous
control. The mRNA levels are presented as fold change relative to
B6 lung. Statistical difference was determined by ANOVA with
Newman-Keuls post-test. *** P\0.001; * P\0.05
Table 5 Polymorphisms in Emilin2 between A/J and B6
Amino acid polymorphisms SNPs in promoter
Position B6 A/J Position B6 A/J
136
a Serine Proline -131 C G
162
a Serine Proline -246 C T
172 Valine Threonine -882 C T
182 Leucine Phenylalanine -1312 G A
258 Serine Threonine -1313 Del C
483 Threonine Alanine -1314 Del A
571 Valine Glycine -1315 Del C
662 Alanine Valine -1316 Del A
834 Glutamine Arginine
917
a Threonine Alanine SNPs in 50-noncoding region
925 Threonine Alanine 156 G del
171 Del G
In the coding region, the amino acid polymorphisms are indicated.
The positions of amino acids are numbered from the starting amino
acid. In the promoter and 50-noncoding regions, the nucleotide
polymorphisms are indicated. In the promoter, the nucleotide before
the putative transcription start site is numbered as -1. In the 50-
noncoding region, the positions are numbered from the putative
transcription start site (as 1)
a Predicted sites for post-translational modiﬁcation
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123database reported 12 nonsynonymous SNPs. There was one
discrepancy with the Sanger database, where two SNPs are
listed at adjacent positions, 71624555 and 71624556, with
respect to our sequencing. Our sequencing revealed that the
two SNPs are within one codon and give rise to one amino
acid change. Two serine (B6)-proline (A/J) substitutions
were detected at residues 136 and 162, and three threonine
(B6)-alanine (A/J) substitutions were detected at 483, 917,
and 925. There was one valine (B6)-threonine (A/J) sub-
stitution at 172 and one glutamine (B6)-arginine (A/J)
substitution at 834. The above seven amino acid changes
have the potential to alter the charges or structures of the
protein. The two serine (B6) with proline (A/J) substitu-
tions at residues 136 and 162 are predicted to have
post-translational modiﬁcations (Lee et al. 2006), and the
threonine (B6) with alanine (A/J) substitution at position
917 is predicted to be a glycosylation site (Lee et al. 2006).
Other amino acid polymorphisms, including leucine (B6)-
phenylalanine (A/J), serine (B6)-threonine (A/J), valine
(B6)-glycine (A/J), and alanine (B6)-valine (A/J), may
have less or no effect on the protein functions. Among the
11 nonsynonymous SNPs in the coding region, six amino
acids are not conserved in mammals (Supplementary
Fig. 1). Two amino acids, Ser162 and Leu182, are con-
served in B6 and other mammals but are changed to proline
and phenylalanine in A/J. In addition, two other amino
acids, proline 136 and alanine 917, are conserved in A/J
and other mammals but are substituted by serine and
threonine in B6. B6 mice and other mammals have con-
served amino acids (threonine and serine) at position 925,
which is substituted to alanine in A/J mice. These ﬁve
amino acid substitutions at the conserved sites have a
potential to confer structural and functional differences of
the protein in A/J versus B6 mice.
To determine whether there are nucleotide polymor-
phisms in the upstream and noncoding regions in Emilin2,
the 1.5-kb upstream region and the 50- and 30-noncoding
mRNA regions were cloned from A/J or B6 mouse
strains (Table 5). No polymorphisms were detected in the
30-noncoding mRNA region. In the 50-noncoding region,
single nucleotide deletions were found in A/J and B6 at two
locations (Table 5). A total of eight SNPs were detected in
the 1.5-kb putative promoter region, including two substi-
tutions in the proximal region and two substitutions and
four deletions (in B6) in the distal region. These SNPs in
the promoter and 50-noncoding region may explain the
differential expression of Emilin2 in certain tissues.
Function of Emilin2 in thrombosis
EMILIN2 was considered to potentially play a direct role
in the formation or stability of the thrombus after injury.
Multimerin1 (Hayward et al. 1993), an EMILIN protein, is
found as a complex with coagulation factor V in platelet a-
granules; it is released to the platelet surface upon platelet
activation and binds to platelets and endothelial cells. A
deﬁciency of Multimerin1 and a-synuclein, a protein that
inhibits a-granule release from platelets, had impaired
platelet adhesion and thrombin formation that was cor-
rected with Multimerin treatment (Reheman et al. 2010).
Whether EMILIN2 plays such a role in thrombosis is not
known. EMILIN2 protein was determined by immuno-
blotting with an anti-peptide antibody. EMILIN2 was
detected in platelets, macrophages, and plasma (Fig. 3).
Full-length EMILIN2 was detected in platelets, but only
fragments of EMILIN2 were detected in aorta. In addition,
fragments of EMILIN2 were also detected in macrophages
and plasma (Fig. 3c, d). In macrophages, a single band at
75 kDa was detected and a single band at 50 kDa was
identiﬁed in plasma. The speciﬁcity (data not shown) of the
EMILIN2 antibody (E185) was veriﬁed by inhibition with
the antigen peptide, identiﬁcation of the full-length protein
and fragments with a commercially available EMILIN2
antibody, and lack of cross-reactivity with EMILIN1
antibodies. The peptide antigen inhibited the full-length
protein as well as the fragments, and an antibody to
EMILIN1 did not cross-react with the full-length, or frag-
ments of, EMILIN2. The commercially available antibody
detected a pattern of EMILIN2 in the tissues similar to that
of the E185 antibody. These results suggested that E185
was speciﬁc for EMILIN2 and that the fragments were not
artifacts. Although we did not detect a difference in B6 and
A/J platelet EMILIN2 in unstimulated platelets or macro-
phages (Fig. 3b, c, e), plasma EMILIN2 was signiﬁcantly
higher in A/J and B6-Chr17 than in B6 mice (Fig. 3d, f),
suggesting a potential role for EMILIN2 in clot stability.
EMILIN2 was also identiﬁed in the thrombus induced by
ferric chloride injury.
Since EMILIN2 was found in the platelets, macro-
phages, and plasma, it was assessed in the thrombi after
ferric chloride injury. EMILIN2 was found in the vessel
wall in the uninjured carotid (Fig. 4a, b) and in the thrombi
after injury (Fig. 4c, d). Quantiﬁcation of the immuno-
staining indicated reduced EMILIN2 in sections from
A/J mice. Identiﬁcation of platelets (Fig. 4e, f) with a
P-selectin antibody suggested a similar pattern of distri-
bution of EMILIN2 in B6 and A/J mice. EMILIN2 was
signiﬁcantly lower in A/J than in B6 mice in the vessel wall
and thrombus. Because EMILIN2 is higher in plasma but
lower in the vessel wall and thrombi in A/J mice, EMILIN2
in A/J may have defects in binding.
A second possible role for EMILIN2 in thrombosis is
that it is critical for maintenance of the vessel wall archi-
tecture. EMILIN1 deﬁciency causes disruptions of the
endothelial cell layer and interferes with elastogenesis
(Zanetti et al. 2004), disrupting the elastic lamina of the
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123vessel wall. Collagen was measured in the vessel wall and
in the tail of B6 and A/J mice. Because there was a twofold
difference in clot stability in the tail bleeding/rebleeding
assay in A/J mice than in B6 mice, collagen (Table 6) was
assessed in the tail and was found to be 27% higher
(P\0.05) in A/J mice than in B6 mice (Hoover-Plow
et al. 2006). The percent of collagen was signiﬁcantly
higher by 45% (P\0.001) in the arteries of A/J mice than
of B6 mice (Table 6). Whether the accumulation of col-
lagen in the A/J mice alters thrombosis and is due to dif-
ferences in EMILIN2 between the B6 and A/J mice is
unclear. The internal and external elastic lamina was
evaluated in injured and uninjured carotids (Table 5).
Unlike the B6 mice, in the A/J mice there was no change in
the elastic lamina after FeCl3-induced injury. In addition,
EMILIN2 was identiﬁed in the vessel wall in uninjured
carotids (Fig. 4). These results suggest that there are
functional differences in the two strains that could be
related to the differences in the vessel wall ECM compo-
sition of the A/J and B6 mice.
Summary
The prolonged clot stability in the bleeding/rebleeding
assay identiﬁed previously in B6-Chr17 mice was con-
ﬁrmed in a direct thrombotic assay of FeCl3-induced car-
otid injury. In B6 mice only 10% of the carotids remained
occluded at 24 h, while in the B6-Chr17 mice 100%
remained occluded. Expression analysis of the 23 homol-
ogous genes in the syntenic region of QTLs for thrombosis
risk in mice and humans revealed 7 genes that had SNPs in
the regulatory regions and altered expression in tissues:
Rab31, Ralbp1, Twsg1, Zfp161, Dlgap1, Myom1, and
Emilin2. Two other genes had nonsynonymous SNPs
without increased expression, Lama1 and Ndc80. These
nine genes are the most likely candidate genes. EMILIN2
is a member of the EMILIN proteins found in the cardio-
vascular system and was selected for further analysis. This
study found high mRNA expression of Emilin2 in bone
marrow compared to other tissues. Sequencing of Emilin2
in B6 or A/J mice identiﬁed SNPs in both coding and
potential regulatory regions. In addition, EMILIN2 protein
differential expression was identiﬁed in plasma, the vessel
wall, and thrombi, suggesting a potential direct role in clot
stability. Furthermore, EMILIN2 in the vessel wall and
altered composition and architecture in B6 and A/J vessel
walls implicates a second potential role of EMILIN2 in the
response to vascular injury.
Discussion
The two QTLs Hmtb8 and Hmtb9, which regulate
clot stability, were previously identiﬁed on mouse Chr 17
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macrophages from B6 and A/J
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123(Sa et al. 2008). These two loci map to a syntenic region
that contains a QTL controlling thrombosis susceptibility
in humans (Soria et al. 2003). There are several genetic
differences that can cause variation in the expression of a
gene: (1) Genes have nonsynonymous SNPs that change
amino acids in the coding region, (2) genes have SNPs in
the regulatory regions, or (3) the gene products differ in
their expression levels (Glazier and Nadeau 2002; Wang
et al. 2005). In addition to identiﬁcation of splice variants
(Marcucci and Romano 2008; Zavolan and van Nimwegen
2006), recent studies have suggested that copy number
variability (Cutler et al. 2007; Graubert et al. 2007; Hen-
richsen et al. 2009; She et al. 2008) and microRNA regu-
lation (Prasad et al. 2009) can cause differences in gene
and gene product expression. This study focused on the
identiﬁcation of SNPs in the homologous genes between
B6 and A/J mice.
There were two genes that had nonsynonymous SNPs:
Lama1 and Ndc80. Lama1 is a basement membrane com-
ponent and is limited primarily to epithelium in both
embryonic development and in adults (Ekblom et al. 2003).
Lama1 deﬁciency in mice is embryonically lethal (Alpy
et al. 2005). Ndc80 is involved in the interface between
centromeres and spindle microtubules, and it’s overex-
pression is associated with tumors (Diaz-Rodriguez et al.
2008). Seven genes that contained SNPs were identiﬁed in
mRNA-UTR and had conﬁrmed differential expression in
B6 and A/J mice: Twsg1, Zfp161, Dlgap1, Ralbp1, Myom1,
Rab31, and Emilin2. Mammalian Tswg1 is associated with
salivary gland epithelial development. Twsg1-deﬁcient
mice have craniofacial and skeletal structure defects and
more than half of the deﬁcient mice exhibit dwarﬁsm and
fail to thrive (MacKenzie et al. 2009; Melnick et al. 2006).
Zfp161 is expressed in neural tissue, is involved in tran-
scription regulation (Numoto et al. 1993), and is linked to a
gene associated with an inheritable developmental disor-
der, holoprosencephaly (Sobek-Klocke et al. 1997).
Dlgap1 is expressed in the brain and neural tissues and
functions in synaptic transmission and cell-cell signaling
(Bouwman et al. 2006; Nguyen et al. 2005). Ralbp1 has
GTPase activity, and homozygous and heterozygous mice
have increased sensitivity to irradiation, oxidative stress,
and impaired glutathione homeostasis (Singhal et al. 2008).
Myom1 is a structural constituent of cytoskeleton and is
involved in muscle contraction (Price and Gomer 1993;
Steiner et al. 1999). Rab31 participates in Golgi vesicle
transport and GTP binding (Rodriguez-Gabin et al. 2009).
It is not apparent that these eight genes discussed above
could be causative genes for thrombosis modiﬁers.
Of the nine candidate genes, Emilin2 seems to be the
most likely candidate for the causative gene for thrombosis.
EMILIN2 is one of the EMILIN (Elastin Microﬁbril
Interface Located Protein) proteins, which are a group of
extracellular matrix glycoproteins (Colombatti et al. 2000).
This family comprises at least four proteins, including
EMILIN1, EMILIN2, Multimerin1, and Multimerin2, with
the major site of expression in the cardiovascular system,
including the vascular wall and platelets (Christian et al.
2001; Hayward et al. 1993; Zacchigna et al. 2006).
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Fig. 4 a-d Sections immunostained with EMILIN2 antibody E185.
a, b Uninjured carotid. c, d Sections immediately after occlusion.
e, f Sections immunostained for P-selectin with antibody. Magniﬁ-
cation 9 100 (a-e). g-i Quantiﬁcation of immunostaining. The values
are mean ± SEM of the percent of EMILIN2/vessel wall (g),
EMILIN2/thrombus (h), and P-selectin/thrombus (i) of six mice per
strain. Six sections were analyzed for each mouse using Image-Pro
Plus software. Statistical differences were determined by t test or
ANOVA and Newman-Kuels post-test. * P\0.05, ** P\0.01
Table 6 Extracellular matrix in vessels of B6 and A/J mice
B6 A/J
Collagen (%)
Artery collagen (%) 33 ± 5 (10) 48 ± 3** (11)
Vein collagen (%) 47 ± 6 (6) 57 ± 4 (11)
Tail collagen (%) 33 ± 4 (5) 42 ± 4* (4)
Carotid injury (ratio injured to
uninjured)
Internal elastic lamina 1.48 ± 0.02 (6) 1.05 ± 0.07** (6)
External elastic lamina 1.36 ± 0.03 (6) 0.96 ± 0.05** (6)
Values are the mean ± SEM. Number of mice indicated in
parenthesis
*P\0.05; **P\0.001 determined by t test
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123EMILIN1 deﬁciency causes disruptions of the endothelial
cell layer and interruptions of the elastic lamellae of large
vessels (Zanetti et al. 2004). Other extracellular proteins,
including elastin (Milewicz et al. 2000), ﬁbulins (Argraves
et al. 2003), ﬁbrillar proteins (Robinson and Godfrey
2000), thrombospondins (Stenina et al. 2007), and colla-
gens (Gould et al. 2005; Malfait et al. 2006), important for
vascular wall architecture, are required for recovery from
injury and prevention of vascular disease. In addition,
ECM proteins, including ﬁbulin1 (Argraves et al. 2003),
thrombospondins (Stenina et al. 2007), and collagen
(Gould et al. 2005; Malfait et al. 2006), are found in plasma
and have been used as biomarkers for cardiovascular
disease.
In this study we report that EMILIN2 may function in
two ways to regulate thrombosis: (1) as a component of the
vascular wall and critical for maintaining the vessel
architecture and response to injury, and (2) as a component
of the thrombus facilitating clot lysis. A recent study
reports downregulation of EMILIN2 in brain arteriovenous
malformations (Sasahara et al. 2007). Furthermore, a
number of proteomic and microarray studies of human
tissues have identiﬁed EMILIN2 in extracellular ﬂuids
(plasma, amniotic, seminal, and synovial), stem cells
(hematopoietic, mesenchymal, and osteoblasts), stimulated
endometrial stromal cells, and cancer cells (lymphocytic
leukemia, hepatic, colorectal, and ovarian cancer). In
addition, microarray data (T. C. Somervaille et al., Record
GSE13693) released in 2009 from GEO analyzed gene
expression in bone marrow cell populations in B6 mice.
Analysis of the data revealed that EMILIN2 was signiﬁ-
cantly increased in mature neutrophils compared to undif-
ferentiated hematopoietic cells (3.6-38-fold, P\0.001).
These studies suggest that EMILIN2 plays important
physiological and pathological roles. The identiﬁcation of
EMILIN2 in plasma in humans as well as in mice supports
the hypothesis that EMILIN2 could play a role in
thrombosis.
Emilin2 mRNA expression has been reported in spleen
and uterus (Braghetta et al. 2004); fetal heart, lung, pla-
centa, and peripheral leukocytes (Doliana et al. 2001);
cochlear basement membrane (Amma et al. 2003); and
optic tissues (Scavello et al. 2005). Emilin2 is expressed in
the vasculature and heart in zebraﬁsh during embryonic
development and in adults (Milanetto et al. 2008). In this
study, both nonsynonymous SNPs and expression differ-
ences for Emilin2 were observed in A/J and B6 mice.
Furthermore, the amino acid changes are the same in A/J
mice and in another strain, 129/svJ (see Supplementary
Fig. 2 and Table 2), which also has prolonged clot stabil-
ity. For the QTLs on chromosome 17, from 66 to 66.6 Mb
in the syntenic region, 98% of the SNPs of 129 and B6
mice are identical, but from 66.6 to 71.9 Mb (including
Emilin2), 99% of the SNPs of A/J and 129 mice are
identical. In the QTL Hmtb4 on chromosome 5, SNPs
in some regions such as 100.3-102.5 Mb (99%) and
105-107.4 Mb (94%), B6 and 129 are similar. On the other
hand, A/J and 129 are similar (99%) in the region from
107.6 to 110 Mb, and B6 and A/J are similar (99%) in the
region from 103.3 to 104.5 Mb. Because of the complexity
feature of this trait, it is hard to hypothesize how the
interactions happen, but we do not exclude epistatic
interactions among loci. The known functions of other
EMILIN proteins, the presence of nonsynonymous SNPs in
Emilin2, and expression differences in A/J and B6 from the
current study strongly suggest further investigation of
Emilin2 as a candidate gene underlying thrombosis
susceptibility.
In this study, prolonged clot stability in A/J and
B6-Chr17, detected in a bleeding/rebleeding assay, was
validated using an assay of direct thrombosis formation and
stability. The prolonged clot stability in A/J and B6-Chr17
mice corresponded well to the elevated mRNA expression
levels of Emilin2 in A/J and B6-Chr17 mice. These data
suggest that the quantitative expression difference of
Emilin2 may also be responsible for the phenotypic dif-
ference between A/J and B6 mice. In addition, the differ-
ence in the clot stability and in the expression of Emilin2
between A/J and B6-Chr17 mice suggests that the causa-
tive genes on Chr 17 have epistatic interactions with genes
on other chromosomes. These ﬁndings are consistent with
our previous hypothesis that there were interacting genes
on Chrs 5 and 17 (Hoover-Plow et al. 2006; Sa et al. 2008).
Our previous studies revealed that the homosomic B6-Chr5
or B6-Chr17 mice had prolonged clot stability as did
the A/J parental strain, but the heterosomic mice
(B6-Chr5 9 B6) F1 or (B6-Chr17 9 B6) F1 had values no
different than B6 mice. In contrast, the F1 mice from a
cross of B6-Chr5 9 B6-Chr17 restored the prolonged clot
stability to the elevated consomic values (Hoover-Plow
et al. 2006). Likewise, other studies (Shavit et al. 2009)
have reported several loci that modify the von Willibrand
factor that is required for platelet aggregation, and Hasstedt
et al. (1998) suggested that there was a modiﬁer gene for
protein C that increases thromboembolism risk.
In conclusion, this study identiﬁes nine candidate genes
on mouse chromosome 17 for thrombosis susceptibility. Of
these candidate genes, Emilin2 is a promising candidate
gene that warrants further investigation. Emilin2 is
expressed in liver, heart, lung, aorta, and most prominently
in bone marrow. Emilin2 is differentially expressed in
liver, lung, and bone marrow in B6 and A/J mice. B6 and
A/J mice have SNPs in Emilin2 in the coding and regula-
tory regions. In this study we report that EMILIN2 may
function to regulate thrombosis as a component of the
vascular wall and is critical for maintaining the vessel
Q. Sa et al.: Thrombosis modiﬁer genes 347
123architecture in response to injury, and/or as a component of
the thrombus-facilitating clot lysis. The identiﬁcation of
novel thrombotic susceptibility genes and their homology
in humans may uncover new diagnostic and therapeutic
factors of thrombotic risk.
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